CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04016571
NCT04016571N/ACompleted

Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis

Belfast Health and Social Care Trust·observational·Posted Jul 11, 2019·Updated Aug 5, 2020

In Brief

An observational study for Cystic Fibrosis. Completed, enrolled 31 participants across 1 site.

Detailed Summary

Cystic fibrosis (CF) is a multisystem disease characterized by viscid secretions in multiple organ systems. Lung infection and damage account for most of the disease burden. Acute changes in respiratory signs and symptoms termed Pulmonary Exacerbations require treatment with intravenous antibiotics and hospital admission. These episodes cause substantial disruption to people's lives and impact on lung function, quality of life and lifespan. Current treatment regimes require improvement but further study is needed to identify who might benefit from a different approach. This observational study aims to assess if multi-dimensional measurements taken during treatment correspond with later treatment response. This may allow us to personalise treatment more effectively in the future and to better understand how individuals respond to treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 11, 2019
Enrollment StartDec 1, 2016
Primary CompletionAug 10, 2018
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.0 years ago